Autolus Therapeutics (AUTL) Accumulated Expenses (2017 - 2025)

Autolus Therapeutics (AUTL) has 9 years of Accumulated Expenses data on file, last reported at $55.8 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Expenses rose 6.73% year-over-year to $55.8 million; the trailing twelve-month figure through Dec 2025 stood at $55.8 million (up 6.73% YoY), and the FY2025 full-year result was $55.8 million, up 6.73% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $55.8 million, up from $52.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $55.8 million in Q4 2025 and bottomed at $23.7 million in Q4 2021.
• The 5-year median for Accumulated Expenses is $37.8 million (2024), against an average of $39.6 million.
• The widest annual swing landed in 2021, when Accumulated Expenses declined 14.81%; it then surged 72.38% in 2022.
• A 5-year view of Accumulated Expenses shows it stood at $23.7 million in 2021, then soared by 72.38% to $40.8 million in 2022, then fell by 2.98% to $39.6 million in 2023, then soared by 32.07% to $52.3 million in 2024, then climbed by 6.73% to $55.8 million in 2025.
• The last three Accumulated Expenses figures came in at $55.8 million (Q4 2025), $52.3 million (Q3 2025), and $51.4 million (Q2 2025), per Business Quant data.

Peer Comparison